Treatment
Pharmacological treatment
Another group of major study by the AAP are dopamine reuptake inhibitors, such as Bupropion which seems to have no adverse effects on babies, but there are not enough data. The AAP classifies this group (as well as the SSRI) as "drug whose effects are unknown and may be disturbing."
The AAP has also studied tricyclic antidepressants. See below some evidence on these drugs:
They are useful in the treatment of postpartum depression when there was no good response to SSRI or when they were already being used by pregnant women, with good clinical response.
They present low levels in milk, but its active metabolite have long half-life (37 hours), which can be harmful to the baby because of serum accumulation.
There were no reports of documented adverse effects from exposure to the following drugs: amitriptyline, nortriptyline, imipramine, desipramine or clorimiprimina.